227 results on '"Gödel, P."'
Search Results
2. Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation
3. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
4. Aspects of Coupled Problems in Computational Electromagnetics Formulations
5. Modelling airborne transmission of SARS-CoV-2 at a local scale
6. Can we learn where people come from? Retracing of origins in merging situations
7. Vadere: An open-source simulation framework to promote interdisciplinary understanding
8. Can we learn where people go?
9. P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL
10. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
11. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
12. Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD
13. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function
14. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
15. Perturbation of gut microbiota decreases susceptibility but does not modulate ongoing autoimmune neurological disease
16. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome
17. Modelling airborne transmission of SARS-CoV-2 at a local scale.
18. P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT
19. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
20. Diagnostik und Therapie von immunvermittelten Nebenwirkungen durch Checkpointinhibitoren in der Intensivmedizin
21. CAR, CRS und Neurotoxizität: schwere Komplikationen der Immuntherapie: Was der Intensivmediziner wissen muss
22. Simultaneous maximum-likelihood reconstruction for x-ray grating based phase-contrast tomography avoiding intermediate phase retrieval
23. Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient
24. Cytokine release syndrome
25. A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes
26. Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia
27. Josephson Junctions defined by a Nano-Plough
28. Perturbation of gut microbiota decreases susceptibility but does not modulate ongoing autoimmune neurological disease
29. MO-0952 A multicentric retrospective analysis of the potential synergy between radiotherapy and CAR T-cells
30. Exploring risk factors for non-response to CAR T-cell therapy in large B-cell lymphoma: A binational multicenter project on potential predictors of outcome
31. Enhancing photoluminescence yields in lead halide perovskites by photon recycling and light out-coupling
32. O pewnych zasadniczych twierdzeniach dotyczących podstaw matematyki i wnioskach z nich płynących (przeł. M. Poręba)
33. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
34. Understanding cytokine release syndrome
35. Sensitivity Analysis for Microscopic Crowd Simulation
36. Does CAR T-Cell Level during Post-CART DLBCL Progression Influence the Response to Salvage Radiotherapy and Patient Outcomes?
37. Cytokine release syndrome
38. P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT
39. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
40. Metabolic Tumor Volume for Outcome Prediction in Patients with Aggressive B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy
41. Metabolic Tumor Volume for Outcome Prediction in Patients with Large B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Treatment
42. Phase I trial of MB-CART2019.1 in patientes with relapsed or refratory B-cell non-Hodgkin lymphoma: 2 year follow-up report [Poster]
43. Microtubule Associated Protein 1b (MAP1B) Is a Marker of the Microtubular Cytoskeleton in Podocytes but Is Not Essential for the Function of the Kidney Filtration Barrier in Mice.
44. Ring-a-Scientist — der direkte Draht ins Labor
45. The 33S(n,α)30Si cross section measurement at n_TOF-EAR2 (CERN): From 0.01 eV to the resonance region
46. Serial circulating tumor DNA sequencing reveals clonal dynamics and can offer treatment guidance in relapsed/refractory diffuse large B‐cell lymphoma.
47. LIQUID‐BIOPSY BASED GENOTYPING OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
48. Influence of the Variation of Material Properties on the Risk of Failure in Dependency of the Materials Flow Condition During Forming Processes
49. Characterization of the flow behavior of deep drawing steel grades in dependency of the stress state and its impact on fea
50. A novel domain regulating degradation of the glomerular slit diaphragm protein podocin in cell culture systems.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.